Results 161 to 170 of about 267,125 (312)

Linezolid‐mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition

open access: yesArthritis &Rheumatology, EarlyView.
Objective Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Because mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and ...
Xuezhi Hong   +13 more
wiley   +1 more source

Late Onset Telomere Biology Disorder Presenting With Pancytopenia, Immune Dysregulation, Interstitial Lung Disease and Alopecia

open access: yes
American Journal of Hematology, EarlyView.
Bo A. Wan   +7 more
wiley   +1 more source

A Cooperative Release of Mitochondrial DNA From Platelets and Neutrophils Drives an Interferon Signature in Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Mitochondria are organelles with a hypomethylated circular genome. Mitochondrial DNA (mtDNA) in the systemic circulation has been implicated in inflammation. This study investigates the role of circulating DNA in systemic sclerosis (SSc) and the cellular mechanisms governing its release.
Stavros Giaglis   +9 more
wiley   +1 more source

Toxic interstitial lung disease in cattle. [PDF]

open access: yesJ Vet Diagn Invest
Barros CSL   +3 more
europepmc   +1 more source

Long‐Term Outcomes of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Systemic Sclerosis Patients with Impaired Cardiac Function

open access: yesArthritis &Rheumatology, Accepted Article.
Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean   +4 more
wiley   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

open access: yesArthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro   +17 more
wiley   +1 more source

Occult Childhood Interstitial Lung Disease. [PDF]

open access: yesBalkan Med J
Li ZQ, Wu XJ.
europepmc   +1 more source

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia   +18 more
wiley   +1 more source

COVID-19 and Interstitial Lung Disease. [PDF]

open access: yesMedicina (Kaunas)
Carbone RG   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy